Abstract
BACKGROUND: It is controversial whether achieving stable disease leads to a survival benefit and whether the importance of achieving stable disease differs between cytotoxic agents and molecular targeted agents. To examine these questions, the authors retrospectively reviewed phase II and III studies in the second-line setting for advanced non-small cell lung cancer using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and cytotoxic agents separately. METHODS: The authors chose 45 trials for the chemotherapy group and nine for the EGFR TKI group by searching the PubMed database. All nine trials in the EGFR TKI group concern gefitinib and erlotinib. RESULTS: The median survival time increased 0.0375 month with each 1% increase in stable disease rate (p = 0.039), and each 1% increase in response rate resulted in 0.0744 (p < 0.001) month of median survival time in the analysis combined with both cytotoxic agents and EGFR TKIs. Main and interaction terms for EGFR TKI treatment were not statistically significant. With respect to time to progression, only response rate showed a statistically significant relationship with survival. CONCLUSIONS: To obtain response seems to be more important than to achieve stable disease for both cytotoxic agents and EGFR TKIs, although achieving stable disease is still valuable. The relationship between survival and response or stable disease appears similar for cytotoxic agents and EGFR TKIs.
| Original language | English |
|---|---|
| Pages (from-to) | 684-691 |
| Number of pages | 8 |
| Journal | Journal of Thoracic Oncology |
| Volume | 1 |
| Issue number | 7 |
| Publication status | Published - Sep 1 2006 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Pulmonary and Respiratory Medicine
Cite this
Is the importance of achieving stable disease different between epidermal growth factor receptor tyrosine kinase inhibitors and cytotoxic agents in the second-line setting for advanced non-small cell lung cancer? / Kurata, Takayasu; Matsuo, Keitaro; Takada, Minoru; Kawahara, Masaaki; Tsuji, Masahiro; Matsubara, Yuka; Otani, Nagahiro; Matsuyama, Shigeki; Muraishi, Kenya; Fujita, Tetsuya; Ishikawa, Masato; Koyano, Keita; Okamoto, Isamu; Satoh, Taroh; Tamura, Kenji; Nakagawa, Kazuhiko; Fukuoka, Masahiro.
In: Journal of Thoracic Oncology, Vol. 1, No. 7, 01.09.2006, p. 684-691.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Is the importance of achieving stable disease different between epidermal growth factor receptor tyrosine kinase inhibitors and cytotoxic agents in the second-line setting for advanced non-small cell lung cancer?
AU - Kurata, Takayasu
AU - Matsuo, Keitaro
AU - Takada, Minoru
AU - Kawahara, Masaaki
AU - Tsuji, Masahiro
AU - Matsubara, Yuka
AU - Otani, Nagahiro
AU - Matsuyama, Shigeki
AU - Muraishi, Kenya
AU - Fujita, Tetsuya
AU - Ishikawa, Masato
AU - Koyano, Keita
AU - Okamoto, Isamu
AU - Satoh, Taroh
AU - Tamura, Kenji
AU - Nakagawa, Kazuhiko
AU - Fukuoka, Masahiro
PY - 2006/9/1
Y1 - 2006/9/1
N2 - BACKGROUND: It is controversial whether achieving stable disease leads to a survival benefit and whether the importance of achieving stable disease differs between cytotoxic agents and molecular targeted agents. To examine these questions, the authors retrospectively reviewed phase II and III studies in the second-line setting for advanced non-small cell lung cancer using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and cytotoxic agents separately. METHODS: The authors chose 45 trials for the chemotherapy group and nine for the EGFR TKI group by searching the PubMed database. All nine trials in the EGFR TKI group concern gefitinib and erlotinib. RESULTS: The median survival time increased 0.0375 month with each 1% increase in stable disease rate (p = 0.039), and each 1% increase in response rate resulted in 0.0744 (p < 0.001) month of median survival time in the analysis combined with both cytotoxic agents and EGFR TKIs. Main and interaction terms for EGFR TKI treatment were not statistically significant. With respect to time to progression, only response rate showed a statistically significant relationship with survival. CONCLUSIONS: To obtain response seems to be more important than to achieve stable disease for both cytotoxic agents and EGFR TKIs, although achieving stable disease is still valuable. The relationship between survival and response or stable disease appears similar for cytotoxic agents and EGFR TKIs.
AB - BACKGROUND: It is controversial whether achieving stable disease leads to a survival benefit and whether the importance of achieving stable disease differs between cytotoxic agents and molecular targeted agents. To examine these questions, the authors retrospectively reviewed phase II and III studies in the second-line setting for advanced non-small cell lung cancer using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and cytotoxic agents separately. METHODS: The authors chose 45 trials for the chemotherapy group and nine for the EGFR TKI group by searching the PubMed database. All nine trials in the EGFR TKI group concern gefitinib and erlotinib. RESULTS: The median survival time increased 0.0375 month with each 1% increase in stable disease rate (p = 0.039), and each 1% increase in response rate resulted in 0.0744 (p < 0.001) month of median survival time in the analysis combined with both cytotoxic agents and EGFR TKIs. Main and interaction terms for EGFR TKI treatment were not statistically significant. With respect to time to progression, only response rate showed a statistically significant relationship with survival. CONCLUSIONS: To obtain response seems to be more important than to achieve stable disease for both cytotoxic agents and EGFR TKIs, although achieving stable disease is still valuable. The relationship between survival and response or stable disease appears similar for cytotoxic agents and EGFR TKIs.
UR - http://www.scopus.com/inward/record.url?scp=34247863893&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34247863893&partnerID=8YFLogxK
M3 - Article
C2 - 17409937
AN - SCOPUS:34247863893
VL - 1
SP - 684
EP - 691
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
SN - 1556-0864
IS - 7
ER -